IsoRay Is Set For Further Growth

  • IsoRay’s proprietary Cesium-131 based therapies have cost, effectiveness and side effect advantages, which are leading to increased application.
  • It is still in the early innings of capturing an increasing market.
  • Besides brachytherapy for prostate cancer, which is the main usage today, the seeds can be used against other cancers, and the company has no international sales yet.
  • We believe the shares have further to run, but keep an eye on cash levels.

Source: IsoRay Is Set For Further Growth – IsoRay, Inc. (NYSEMKT:ISR) | Seeking Alpha